Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2NET 1Endocrine 1

Conditions

Carcinoma, Hepatocellular 2Neuroendocrine Tumors 1Hypoxia 1

Interventions

Sorafenib 26Nivolumab 21pembrolizumab 15Bevacizumab 14lenvatinib 12atezolizumab 9Cyclophosphamide 9Ipilimumab 8durvalumab 6camrelizumab 5apatinib 5Specimen Handling 5Radiosurgery 5tislelizumab 4fludarabine 4Immunotherapy, Adoptive 4Fluorouracil 4Doxorubicin 4tremelimumab 3toripalimab 3sintilimab 3regorafenib 3cabozantinib 3X-Rays 3Magnetic Resonance Spectroscopy 3Injections 3Everolimus 3Ethiodized Oil 3Erlotinib Hydrochloride 3tepotinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Hepatocellular × Tirapazamine × Clear all
NCT02174549 2026-04-20

Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Teclison Ltd.

Phase 1/2 Recruiting
25 enrolled
EndocrineGastrointestinalNET

Hypoxia, Carcinoma, Hepatocellular, Neuroendocrine Tumors

NCT06848556 2025-02-27

Evaluate the Effect of Tirazamine on Primary Liver Cancer.

Zhejiang Raygene Pharmaceuticals Co., Ltd

Phase 1/2 Terminated
16 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡